Qiagen reported a 2% rise in quarterly revenue on Tuesday, driven by strong demand for its COVID-19 testing products.
The genetic testing specialist posted net sales of $581 million in the fourth quarter, up from $571 million a year earlier.
Marketzone with Reuters 2022
|
|
| ||||
QIAGEN NV Technical Analysis Trends
| Short term | Middle term | Long term | |
| Trends | Bearish | Bearish | Neutral |
Evolution of the Income Statement
Sale  Purchase | |
| Average recommendation | ACCUMULATE |
| Number of Analysts | 14 |
| Last Closing Price | $49.22 |
| Average price target | $57.79 |
| Deviation / Average Target | 17.4% |
Officers and Directors